Sun, Mar 26, 2017
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Alternative Market Briefing

Ackman to pursue Allergan acquisition, a new corporate actions model emerges

Tuesday, April 22, 2014

Bailey McCann, Opalesque New York:

As Opalesque recently reported, investors are lining up for activist strategies. Those investors may be interested in the latest news from Pershing Square CEO Bill Ackman who is teaming up with Valeant Pharmaceuticals International Inc. seek to acquire the botox maker, Allergan Inc. The partnership was first reported late yesterday afternoon and marks another high profile bet for the activist who has recently staked out positions on Herbalife and JC Penny.

Valeant owns other well known brands including Bausch & Lomb and focuses heavily on eye-care. According to reports, Valeant has been trying to acquire Allergan for some time, but this acquisition attempt is likely to be hostile. Both companies posted gains in after hours trading.

The New York Times notes that if the bid is successful, a hedge fund teaming up with a corporation could provide a new model for corporate actions. The deal would have to be approved by regulators which are likely to give the transaction close scrutiny given the possibility for conflicts of interest. ......................

To view our full article Click here

Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing

 



  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Hedge fund liquidations in 2016 surpass 2009 levels, new launches decline[more]

    Benedicte Gravrand, Opalesque Geneva: Even as the hedge fund industry's total assets exceeded the $3tln milestone last year, hedge fund liquidations increased. So much so that 2016 had the highest number of liquidations since 2008, claims the latest HFR Market Microstructure Report, re

  2. Hedge funds find no joy in macro as returns lag Trump rally[more]

    From Gulfnews.com: In 2017, macro hedge funds were expected to shine. So far? Not so much. It's been a far from impressive first two months for funds that trade around macroeconomic events. Discretionary funds rose just 0.3 per cent through February, according to Hedge Fund Research Inc., while the

  3. Strategies - Billionaire investor Marc Lasry shares how he's playing markets right now, Classic models are failing FX hedge funds desperate for return[more]

    Billionaire investor Marc Lasry shares how he's playing markets right now From CNBC.com: Buy on the prospect of deregulation. Sell on the enactment of deregulation. That's the strategy that billionaire investor Marc Lasry is implementing, according to an interview with CNBC in Las Vegas

  4. Opalesque Exclusive: Aberdeen makes the case for the lower mid-market[more]

    Bailey McCann, Opalesque New York: Aberdeen Asset Management has released a new paper focused on lower mid-market private equity. According to the paper, this segment of the private equity market is gaining popularity with private equity investors that are looking for multiple expansion and less

  5. Hedge funds await outcome of French elections, feel pinch on lower oil prices & weak dollar[more]

    Komfie Manalo, Opalesque Asia: Hedge funds felt the pinch of lower oil prices and weak U.S. dollar as the Lyxor Hedge Fund Index was marginally down as of the week ending 14 March, Lyxor Asset Management said in its Weekly Briefing. The Lyxor He